02963nam a22004575i 4500001001800000003000900018005001700027007001500044008004100059020001800100024003500118050001400153072001600167072002300183072001500206245013700221250001800358264006900376300006500445336002600510337002600536338003600562347002400598490006100622505080800683520047301491650001801964650002401982650002302006650001802029650002502047700007902072700007902151710003402230773002602264776003602290776003602326776003602362830006102398856004602459978-3-031-75806-5DE-He21320251030113321.0cr nn 008mamaa241121s2024    sz |    s    |||| 0|eng d  a97830317580657 a10.1007/978-3-031-75806-52doi 4aRM300-666 7aMMG2bicssc 7aMED0710002bisacsh 7aMKG2thema10aPublic-Private-Partnerships in Drug Research and Developmenth[electronic resource] /cedited by Martin C. Michel, Heike A. Wieland.  a1st ed. 2024. 1aCham :bSpringer Nature Switzerland :bImprint: Springer,c2024.  aXI, 196 p. 100 illus., 30 illus. in color.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda1 aHandbook of Experimental Pharmacology,x1865-0325 ;v2860 aNovel and proven models of Public Private and Public Private Partnerships in Healthcare An Update -- Project based Public private collaborations -- Collaborative Innovations in Childhood Cancer Therapies -- Reaching outer space and enabling the mRNA revolution a critical role of partnerships for successful drug and vaccine development -- The Alliance between the German Cancer Research Center and Bayer a retrospective of an innovative collaboration model -- Life Science Incubation at LabCentral BioLabs with Partners Extending from the US to Europe -- Innovation at the Interface between Academia and Industry The BioMed X Model -- From innovator result driven to multi actor impact oriented Public Private Partnerships Integrating the patient perspective -- The Legal Framework for PPP in Drug R&D.  aCollaborative approaches are becoming a key driver in drug discovery and development. They come in many types and forms ranging from project-based collaborations and strategic alliances to large international consortia. The volume discusses various types of such collaboration including the specific uses, advantages, and challenges. Based on the nature of public-private partnerships, we present views and experiences from academia, industry, and public stakeholders. 0aPharmacology. 0aMedicinexResearch. 0aBiologyxResearch.14aPharmacology.24aBiomedical Research.1 aMichel, Martin C.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aWieland, Heike A.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt2 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978303175805808iPrinted edition:z978303175807208iPrinted edition:z9783031758089 0aHandbook of Experimental Pharmacology,x1865-0325 ;v28640uhttps://doi.org/10.1007/978-3-031-75806-5